Managing myelodysplastic syndromes in very old patients: a teaching case report

Pasquale Niscola, Massimiliano Palombi, Malgorzata Monika Trawinska, Andrea Tendas, Marco Giovannini, Laura Scaramucci, Alessio Perrotti, Paolo de Fabritiis Hematology Unit, Sant'Eugenio Hospital, Rome, Italy Abstract: The introduction of hypomethylating agents in the treatment of myelodysp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Niscola P, Palombi M, Trawinska MM, Tendas A, Giovannini M, Scaramucci L, Perrotti A, de Fabritiis P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	myelodysplastic syndromes azacitidine older patients Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/4b5a965fe9244854bc76692f07bfa05e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4b5a965fe9244854bc76692f07bfa05e
record_format	dspace
spelling	oai:doaj.org-article:4b5a965fe9244854bc76692f07bfa05e2021-12-02T07:46:00ZManaging myelodysplastic syndromes in very old patients: a teaching case report1178-1998https://doaj.org/article/4b5a965fe9244854bc76692f07bfa05e2013-04-01T00:00:00Zhttps://www.dovepress.com/managing-myelodysplastic-syndromes-in-very-old-patients-a-teaching-cas-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Pasquale Niscola, Massimiliano Palombi, Malgorzata Monika Trawinska, Andrea Tendas, Marco Giovannini, Laura Scaramucci, Alessio Perrotti, Paolo de Fabritiis Hematology Unit, Sant'Eugenio Hospital, Rome, Italy Abstract: The introduction of hypomethylating agents in the treatment of myelodysplastic syndromes (MDS) has significantly changed the clinical scenario of these diseases, which afflict predominantly older individuals. However, some concerns regarding the optimal application of these innovative and costly agents in the treatment of geriatric high-risk MDS remain. We report here the case of a nonagenarian treated with hypomethylating agents achieving a long-lasting clinical response and a significant improvement in her functional status. Our case confirmed that functional status and biological status, rather than the chronological age alone, can substantially guide the plan of an appropriate treatment strategy in high-risk MDS patients; moreover, the current case emphasizes the need for targeted studies in the field of geriatric MDS in order to formulate guidelines on the appropriate use of these costly agents, so that candidate patients can receive adequate treatment to preserve their quality of life and life expectancy, but at the same time avoiding unnecessary costs deriving from the use of high-cost drugs for those in whom a significant therapeutic result cannot be reasonably expected. Keywords: myelodysplastic syndromes, azacitidine, older patientsNiscola PPalombi MTrawinska MMTendas AGiovannini MScaramucci LPerrotti Ade Fabritiis PDove Medical Pressarticlemyelodysplastic syndromesazacitidineolder patientsGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 391-394 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	myelodysplastic syndromes azacitidine older patients Geriatrics RC952-954.6
spellingShingle	myelodysplastic syndromes azacitidine older patients Geriatrics RC952-954.6 Niscola P Palombi M Trawinska MM Tendas A Giovannini M Scaramucci L Perrotti A de Fabritiis P Managing myelodysplastic syndromes in very old patients: a teaching case report
description	Pasquale Niscola, Massimiliano Palombi, Malgorzata Monika Trawinska, Andrea Tendas, Marco Giovannini, Laura Scaramucci, Alessio Perrotti, Paolo de Fabritiis Hematology Unit, Sant'Eugenio Hospital, Rome, Italy Abstract: The introduction of hypomethylating agents in the treatment of myelodysplastic syndromes (MDS) has significantly changed the clinical scenario of these diseases, which afflict predominantly older individuals. However, some concerns regarding the optimal application of these innovative and costly agents in the treatment of geriatric high-risk MDS remain. We report here the case of a nonagenarian treated with hypomethylating agents achieving a long-lasting clinical response and a significant improvement in her functional status. Our case confirmed that functional status and biological status, rather than the chronological age alone, can substantially guide the plan of an appropriate treatment strategy in high-risk MDS patients; moreover, the current case emphasizes the need for targeted studies in the field of geriatric MDS in order to formulate guidelines on the appropriate use of these costly agents, so that candidate patients can receive adequate treatment to preserve their quality of life and life expectancy, but at the same time avoiding unnecessary costs deriving from the use of high-cost drugs for those in whom a significant therapeutic result cannot be reasonably expected. Keywords: myelodysplastic syndromes, azacitidine, older patients
format	article
author	Niscola P Palombi M Trawinska MM Tendas A Giovannini M Scaramucci L Perrotti A de Fabritiis P
author_facet	Niscola P Palombi M Trawinska MM Tendas A Giovannini M Scaramucci L Perrotti A de Fabritiis P
author_sort	Niscola P
title	Managing myelodysplastic syndromes in very old patients: a teaching case report
title_short	Managing myelodysplastic syndromes in very old patients: a teaching case report
title_full	Managing myelodysplastic syndromes in very old patients: a teaching case report
title_fullStr	Managing myelodysplastic syndromes in very old patients: a teaching case report
title_full_unstemmed	Managing myelodysplastic syndromes in very old patients: a teaching case report
title_sort	managing myelodysplastic syndromes in very old patients: a teaching case report
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/4b5a965fe9244854bc76692f07bfa05e
work_keys_str_mv	AT niscolap managingmyelodysplasticsyndromesinveryoldpatientsateachingcasereport AT palombim managingmyelodysplasticsyndromesinveryoldpatientsateachingcasereport AT trawinskamm managingmyelodysplasticsyndromesinveryoldpatientsateachingcasereport AT tendasa managingmyelodysplasticsyndromesinveryoldpatientsateachingcasereport AT giovanninim managingmyelodysplasticsyndromesinveryoldpatientsateachingcasereport AT scaramuccil managingmyelodysplasticsyndromesinveryoldpatientsateachingcasereport AT perrottia managingmyelodysplasticsyndromesinveryoldpatientsateachingcasereport AT defabritiisp managingmyelodysplasticsyndromesinveryoldpatientsateachingcasereport
_version_	1718399151779086336

Managing myelodysplastic syndromes in very old patients: a teaching case report

Ejemplares similares